Share with your friends

Pharma 2030: From evolution to revolution

We believe that pharmaceutical revenues will fall well short of forecasts.

20 April 2017, 3:00PM - 4:00PM, CST



We believe that pharmaceutical revenues will fall well short of forecasts, as current projections, as well as business and operating models, do not reflect the turbulence in the marketplace.

Two seismic shifts are impacting the industry: the need to demonstrate value from therapies; and the move from treatment to prevention, diagnostics and cure, all of which is bringing in a host of new competitors.

To rise to this challenge, executive teams need to choose which of the following three ‘archetypes’ they want their organization to become:

  1. Active pharmaceutical portfolio company
  2. Virtual value chain orchestrator
  3. Pharmaceutical niche specialist

Those pharmaceutical companies that manage to embrace the most appropriate archetypes, and master disruption, have the greatest chance to deliver real value to patients and be successful in the new, disrupted world.

Join Roger van den Heuvel, Global Strategy Group Life Sciences Head, and Professor Hilary Thomas, Chief Medical Advisor, who will be present their perspectives on these issues and take questions. The full publication can also be accessed here.

This webcast is a must for C-suite and directors who operate within the life sciences sector.  Should you believe that someone within your organization would benefit from participating, please feel free to forward this email.

After registering for this webcast via the links above, you will receive details on how to access the webcast. The webcast will last approximately 60 minutes including a question and answer period.

If you have any questions or comments, please contact Thomas Bailey via email or by phone: +86 21 2212 2367




dna molecules

Connect with us


Want to do business with KPMG?


loading image Request for proposal